Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesTransplantAetna hematopoietic cell transplant Coverage | Ope…
    Ask Trek AI about this page
    CurrentAetnaPolicy 0635

    Hematopoietic Cell Transplantation for Ovarian Cancer

    Customize your policy alerts

    Sign up for Aetna Policy 0635 alerts

    Get alerted when Policy 0635 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs Aetna's medical necessity and investigational determinations for autologous and allogeneic hematopoietic cell transplantation (HCT) in patients with ovarian cancer, including which transplant types and clinical situations are covered or considered experimental.

    Policy Summary
    PayerAetna
    PolicyHematopoietic Cell Transplantation for Ovarian Cancer
    Policy CodePolicy 0635
    Change TypeNo material change
    Effective DateAug 16, 2002
    Last ReviewSep 13, 2023
    Next Review DateJul 11, 2024
    Key ActionObtain prior authorization and document that the indication matches a medically necessary scenario (e.g., relapsed germ cell tumor responsive to standard chemotherapy) before submitting claims for covered HCT codes.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    3Medically necessary scenarios
    3Experimental/investigational scenarios
    38232,38241,S2150Key procedure codes
    07/11/2024Next review

    Coverage Criteria — Hematopoietic Cell Transplantation for Ovarian Cancer

    Medically Necessary

    Aetna considers the following types of hematopoietic cell transplantations medically necessary for treatment of certain ovarian cancers when criteria are met:

    Medically necessary scenarios: 1) Autologous hematopoietic cell transplantation for treatment of relapsed germ cell tumors of the ovary that were responsive to standard chemotherapy.

    Coverage requires prior responsiveness to standard chemotherapy per policy; listed as medically necessary when criteria are met.

    Medically necessary scenarios: 2) Autologous hematopoietic cell transplantation as consolidation therapy for germ cell tumors of the ovary that are in complete remission.

    Used as consolidation in complete remission per policy.

    Medically necessary scenarios: 3) Tandem autologous hematopoietic cell transplantation for germ cell tumors of the ovary that are in relapse.

    Tandem autologous HCT in relapse is listed as medically necessary when criteria are met.

    Experimental / Investigational

    Hematopoietic cell transplantation is considered experimental and investigational in the following scenarios because effectiveness has not been established:

    Experimental/Investigational scenarios: 1) Autologous hematopoietic cell transplantation for initial treatment (i.e., instead of an initial course of standard-dose chemotherapy with FDA‑approved drugs) of germ cell tumors of the ovary.

    Designated investigational because effectiveness as initial therapy is not established.

    Experimental/Investigational scenarios: 2) Allogeneic hematopoietic cell transplantation for the treatment of germ cell tumors of the ovary.

    Allogeneic HCT for germ cell tumors of the ovary is listed as investigational.

    Experimental/Investigational scenarios: 3) Hematopoietic cell transplantation (autologous or allogeneic) for the treatment of epithelial ovarian cancers.

    HCT for epithelial ovarian cancers is considered investigational due to insufficient evidence of effectiveness.

    This policy addresses hematopoietic cell transplantation (HCT) for ovarian cancer and defines the clinical situations in which HCT is considered medically necessary. Specifically, autologous HCT is recognized as medically necessary when used for: (1) treatment of relapsed germ cell tumors of the ovary that were responsive to standard chemotherapy; (2) consolidation therapy in germ cell tumors of the ovary that are in complete remission; and (3) planned tandem autologous HCT for relapsed germ cell tumors. These scenarios are contingent on documentation that the patient’s clinical course and prior treatment response meet the policy’s selection criteria.

    The sections of the document that follow the core coverage statements are primarily reference material. These reference pages compile the clinical studies, registry reports, and guideline sources underlying the policy and do not themselves state additional exclusions or expand the specific medical necessity criteria listed in the policy statements.

    Where the policy designates a use as experimental and investigational, it states that effectiveness has not been established; therefore those uses are considered not medically necessary. Examples identified in the policy include: (1) autologous HCT as an initial (first-line) treatment instead of standard-dose chemotherapy for germ cell tumors of the ovary; (2) allogeneic HCT for germ cell tumors of the ovary; and (3) any HCT (autologous or allogeneic) for epithelial ovarian cancers.

    The provided Policy History and administrative pages summarize review dates and versioning but do not contain additional explicit not medically necessary statements beyond those already stated in the policy’s Experimental and Investigational section.

    Candidate Selection Criteria for Transplant

    Candidate criteria for HCT

    Candidate selection criteria are implied by the medically necessary scenarios and prior responsiveness to standard therapy.

    Autologous HCT for relapsed germ cell tumors: Patient has a relapsed germ cell tumor of the ovary AND the tumor demonstrated responsiveness to prior standard chemotherapy.

    Responsiveness to standard chemotherapy is required for coverage of autologous HCT in relapse.

    Autologous HCT as consolidation: Patient has a germ cell tumor of the ovary AND is in complete remission and autologous HCT is being used as consolidation therapy.

    Complete remission must be documented when HCT is used for consolidation.

    Tandem autologous HCT: Patient has a relapsed germ cell tumor of the ovary AND a plan for tandem autologous hematopoietic cell transplantation.

    Tandem autologous HCT is permitted for relapse when criteria are met.

    Pre-Transplant Evaluation Requirements

    Prior Authorization

    Obtain prior authorization for HCT procedure/HCPCS codes

    Prior authorization is required for procedure codes for hematopoietic cell transplantation (HCT); covered codes (e.g., CPT 38232, 38241 and HCPCS S2150) are allowed only when the policy's selection criteria for medically necessary HCT are met, and allogeneic transplant CPT codes (e.g., 38205, 38240) are listed as not covered for the indications in this bulletin.

    • Covered CPT codes when selection criteria met: 38232, 38241; Covered HCPCS when selection criteria met: S2150.
    • CPT codes for allogeneic HCT (e.g., 38205, 38240) are listed as not covered for the indications in this policy.

    Contraindications and Limitations

    The policy and supporting commentary note that allogeneic transplantation is not generally recommended for ovarian cancer in most contexts and is considered developmental or restricted to very specific settings. The document does not list absolute contraindications by name; instead, it limits use of allogeneic HCT based on available evidence, recommending autologous approaches primarily within approved protocols or selected patients.

    Provider Actions, Prior Authorization, and Documentation

    Prior Authorization

    Obtain prior authorization for HCT procedure codes and confirm selection-criteria eligibility

    Prior authorization is required for the listed CPT and HCPCS transplant codes; coverage for the covered codes (e.g., 38232, 38241, S2150) is permitted only when the policy's selection criteria for medical necessity are met.

    • Submit PA for CPT codes 38232 and 38241 and HCPCS S2150 when requesting autologous HCT.
    • Requests for allogeneic codes (e.g., 38205, 38240) should note that those CPT codes are listed as not covered for indications in this bulletin.
    Note

    No specific PA submission instructions in this policy excerpt

    The provided document portion does not specify detailed prior authorization procedures or required forms; providers should follow standard Aetna PA submission processes as no PA workflow details are included here.

    • No explicit PA submission steps or forms are specified in the cited portions of the policy.

    Procedure and Diagnosis Codes

    Covered CPT Codes (if selection criteria met)CPTCovered
    38232Bone marrow harvesting for transplantation; autologous.
    38241Hematopoietic progenitor cell (HPC); autologous transplantation.
    CPT Codes not covered for indications in the CPBCPTNot Covered
    38205Blood-derived hematopoietic progenitor cell harvesting for transplantation, per collection; allogenic.
    38240Hematopoietic progenitor cell (HPC); allogeneic transplantation per donor.
    Other related CPT code rangesCPT
    38206-38215Bone marrow or stem cell services/procedures.
    96401-96549Chemotherapy administration.
    Covered HCPCS Codes (if selection criteria met)HCPCSCovered
    S2150Bone marrow or blood-derived stem cells (peripheral or umbilical), allogeneic or autologous, harvesting, transplantation, and related complications; including: pheresis and cell preparation/storage; marrow ablative therapy; drugs, supplies, hospitalization with outpatient follow-up; medical/surgical, diagnostic, emergency, and rehabilitative services; and the number of days of pre- and post-transplant care in the global definition.
    ICD-10 Codes referencedICD-10
    C56.1-C56.9Malignant neoplasm of ovary [relapsed germ cell tumors].
    C57.4Malignant neoplasm of uterine adnexa, unspecified [relapsed germ cell tumors].

    Center and Protocol Requirements

    Billing Rule

    Center and coding rules: autologous allowed in protocols; allogeneic generally not recommended

    HCPCS and CPT transplant-related codes (including S2150, 38232, 38241) are listed as covered only if selection criteria are met; allogeneic CPT codes 38205 and 38240 are listed as not covered for indications in this bulletin.

    • Confirm and document that selection criteria are met before billing covered codes (38232, 38241, S2150).
    • Do not bill for allogeneic transplant CPTs 38205 or 38240 for indications listed as not covered in this bulletin.

    Post-Transplant Global Care and Billing

    Global transplant care (HCPCS S2150)
    HCPCS codeS2150: Bone marrow or blood-derived stem cells (peripheral or umbilical), allogeneic or autologous, harvesting, transplantation, and related complications; includes pheresis and cell preparation/storage; marrow ablative therapy; drugs, supplies, hospitalization with outpatient follow-up; medical/surgical, diagnostic, emergency, and rehabilitative services; and the number of days of pre- and post-transplant care in the global definition.
    Scope of global definitionIncludes harvesting, transplantation, related complications, marrow ablative therapy, drugs and supplies, hospitalization with outpatient follow-up, and peri‑transplant services.
    Pre- and post-transplant careS2150 explicitly includes the number of days of pre- and post-transplant care in its global definition when covered.
    Service components includedPheresis and cell preparation/storage, inpatient hospitalization, outpatient follow-up, and rehabilitative services are specified as part of the global code.
    Coverage conditionalityS2150 is listed as covered only if selection criteria in the policy are met (i.e., when the transplant indication satisfies the policy's medical necessity criteria).

    Background and Disease Overview

    Ovarian cancer is predominantly an epithelial carcinoma (about 90% of cases), with less common germ cell and stromal tumors. Standard initial management for ovarian cancer is cytoreductive surgery followed typically by platinum- and taxane-based chemotherapy. The policy recognizes that high-dose chemotherapy (HDC) with hematopoietic stem cell support has been studied, but for epithelial ovarian cancer HDC/HCT remains experimental and should be restricted to clinical trials; by contrast, selected uses of autologous HCT have a role in relapsed germ cell tumors responsive to standard chemotherapy.

    Definitions

    Epithelial ovarian carcinoma — definition and prevalence
    DefinitionEpithelial ovarian carcinoma: malignancy arising from the germinal epithelium of the ovary.
    Prevalence among ovarian cancersApproximately 90% of all ovarian cancers are epithelial ovarian carcinomas.
    Demographics and impactEpithelial ovarian cancer accounts for about 4% of all cancers in women and is the leading cause of death among gynecologic malignancies.
    Typical presentationNearly 70% of patients with epithelial ovarian cancer present with advanced (FIGO stage III–IV) disease at diagnosis due to lack of early symptoms and reliable screening.
    Germ cell tumors of the ovary — definition and clinical notes
    DefinitionGerm cell tumors of the ovary: uncommon ovarian malignancies of germ cell origin, including dysgerminomas and other germ cell histologies.

    Policy History & References

    2023-09-13last_reviewLatest

    Policy last reviewed on 09/13/2023.

    2002-08-16effective

    Policy effective date established as 08/16/2002.

    2024-07-11next_review

    Next scheduled review set for 07/11/2024.

    Policy Summary
    PayerAetna
    PolicyHematopoietic Cell Transplantation for Ovarian Cancer
    Policy CodePolicy 0635
    Change TypeNo material change
    Effective DateAug 16, 2002
    Last ReviewSep 13, 2023
    Next Review DateJul 11, 2024
    Key ActionObtain prior authorization and document that the indication matches a medically necessary scenario (e.g., relapsed germ cell tumor responsive to standard chemotherapy) before submitting claims for covered HCT codes.
    SourceLink
    On This Page
    Coverage Criteria — Hematopoietic Cell Transplantation for Ovarian CancerCandidate Selection Criteria for TransplantPre-Transplant Evaluation RequirementsContraindications and LimitationsProvider Actions, Prior Authorization, and DocumentationProcedure and Diagnosis CodesCenter and Protocol RequirementsPost-Transplant Global Care and BillingBackground and Disease OverviewDefinitionsPolicy History & References
    Step Therapy

    Sequence HCT after standard chemotherapy—document prior therapy and response

    HCT is not defined as formal step therapy, but the policy indicates HCT is reserved for after standard chemotherapy (e.g., for relapsed germ cell tumors responsive to standard chemotherapy) or as consolidation in complete remission.

    • Do not interpret policy as requiring a formal step-therapy prior authorization pathway; instead document that standard therapy was given and response assessed per medical necessity criteria.
    Note

    No step therapy rules present in references/administrative sections

    No formal step therapy rules are specified in the reference and administrative sections of the provided policy excerpts; administrative/reference material does not impose additional step therapy steps.

    • Rely on the clinical selection criteria in the Medical Necessity section rather than any separate step-therapy algorithm in these chunks.
    Documentation Required

    Document indication aligning with medically necessary scenarios

    Document that the requested transplant indication matches one of the medically necessary scenarios (e.g., autologous HCT for relapsed germ cell tumor responsive to standard chemotherapy; autologous HCT as consolidation in complete remission; or tandem autologous HCT for relapsed germ cell tumor).

    • Include clinical history showing prior chemotherapy regimens and evidence of chemosensitivity or complete remission as applicable.
    • Specify whether the request is for autologous versus allogeneic HCT and the clinical rationale tied to the policy's medically necessary scenarios.
    Note

    Policy history present; no extra documentation steps listed here

    Policy history and review dates are provided in the document, but these chunks do not specify any additional required documentation steps beyond clinical indication documentation.

    • Note policy last review date (09/13/2023) and effective date (08/16/2002) when referencing policy versioning for prior authorization discussions.
    Denial Risk

    Expect denial for specified experimental/investigational HCT indications

    Requests for autologous HCT as initial (first-line) treatment of germ cell tumors of the ovary, any allogeneic HCT for germ cell tumors of the ovary, and any HCT (autologous or allogeneic) for epithelial ovarian cancers are considered experimental/investigational and may be denied.

    • If the request is for any of these scenarios, expect an investigational determination and potential denial per the policy.
    • Provide evidence if disputing an investigational determination that demonstrates effectiveness beyond the investigational contexts listed.
    Note

    No additional provider actions specified in these administrative/reference chunks

    The chunks cited here contain administrative and reference material only and do not specify additional provider actions or requirements beyond those noted elsewhere in the policy.

    • Use clinical sections of the policy (Medical Necessity, Background) for actionable documentation and PA requirements rather than the policy history or references sections.
    Clinical characteristicsOften aggressive tumors that occur most frequently in young women and adolescent girls.
    Histology and presentationApproximately 50% of germ cell malignancies are pure dysgerminomas; about 70% of dysgerminomas are confined to the ovary at diagnosis.
    Role in transplant policyAutologous hematopoietic cell transplantation is addressed in the policy primarily for relapsed or consolidation treatment of germ cell tumors of the ovary.
    High‑dose chemotherapy with hematopoietic stem cell support — definition
    DefinitionHigh‑dose chemotherapy with hematopoietic stem cell support: use of escalated‑dose chemotherapeutic regimens followed by infusion of autologous or allogeneic hematopoietic stem cells to rescue marrow function.
    PurposeDesigned to permit administration of myeloablative or near‑myeloablative chemotherapy doses that would otherwise cause irreversible marrow failure.
    Support modalitiesSupport is provided via autologous or allogeneic hematopoietic stem cell infusion (bone marrow or peripheral blood stem cells).
    Evidence baseMultiple clinical studies and trials (references cited in the policy) have evaluated high‑dose chemotherapy and stem cell support in ovarian and germ cell tumors.

    References cited in support of this policy include clinical trials, registry analyses, and reviews of high-dose chemotherapy and stem cell transplantation in ovarian and germ cell tumors. The bibliography lists sources numbered 1 through 41 and includes randomized trials, phase II/III studies, registry reports from the European Group for Blood and Marrow Transplantation, and other relevant oncology literature that underpin the policy’s conclusions.